Dr. Lal Pathlabs Ltd

Dr. Lal Pathlabs Annual General Meeting

Dr. Lal PathLabs issued a Postal Ballot Notice seeking member approval to appoint Ms. Vasuta Agarwal as Independent Director for a three-year term.

Dr. Lal Pathlabs Management Change

Dr. Lal Path Labs appointed Ms. Vasuta Agarwal as an additional Non-Executive Independent Director for three years from 4 November 2026. Her appointment is subject to member approval by postal ballot.

Execution

36 months from 04-11-2026

Dr. Lal Pathlabs Capital Structure Change

Dr. Lal PathLabs will invest up to Rs 49.5 Crore in its wholly owned Dubai subsidiary, in tranches. Funds cover operations and further investment in Ghana's SHL.

Value

₹49.50 Cr

Execution

Indicative completion by 31 March 2027, in tranches

Dr. Lal Pathlabs Dividend

Dr. Lal Path Labs approved a Rs 5 per share second interim dividend. Record date is November 11, 2026; payment by December 3, 2026.

Dr. Lal Pathlabs Investor Presentation: Key Takeaways

Q2 FY27 revenue Rs 874 Cr (+19.6%), EBITDA Rs 280 Cr (32.1% margin), PAT Rs 194 Cr (+27.5%). Strategy: AI diagnostics, rural GraminFit, M&A.

Dr. Lal Pathlabs Q2 FY27 Results: Net Profit ₹193.9 Cr, Up 27.4% YoY

Dr. Lal Pathlabs Ltd reported revenue from operations of ₹873.9 Cr (+19.6% YoY) and net profit of ₹193.9 Cr (+27.4% YoY) for Q2 FY27.

Key figure

Net profit ₹193.9 Cr · +27.4% YoY

Dr. Lal Pathlabs Board Meeting Date

Dr. Lal PathLabs updated its 4 November 2026 board meeting notice to add a possible second interim dividend. The meeting will also approve unaudited quarterly results.

Dr. Lal Pathlabs Acquisition Worth ₹30.3 Cr

Dr. Lal PathLabs subscribed to WOS PUPL equity to fund PUPL's buyout of remaining 30% in CentraPath Labs for ₹30.3 Crore. CentraPath becomes a wholly owned subsidiary.

Value

₹30.30 Cr

Dr. Lal Pathlabs Other Announcement

Dr. Lal PathLabs submitted the quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, received from its RTA.

Dr. Lal Pathlabs Legal & Regulatory

Dr. Lal PathLabs disclosed an ITAT tax appeal against a favorable order for Rs.32.66 Crore ESOP expense relief (AY 2022-23). The company expects no material financial impact.

Value

₹32.66 Cr

Dr. Lal Pathlabs Other Announcement

Dr. Lal PathLabs reported PIT disclosures for trades by designated persons and its Employee Welfare Trust, totaling approximately ₹0.83 Crore. These involved ESOP allotments and market sales.

Value

₹0.09 Cr

Dr. Lal Pathlabs Acquisition Worth ₹38 Cr

Dr. Lal Path Labs' subsidiary completed the acquisition of an 80% stake in Sunshine Healthcare Limited, Ghana, for Rs.38.00 Crore. The target is now a subsidiary.

Value

₹38.00 Cr

Dr. Lal Pathlabs Acquisition

Dr. Lal PathLabs' subsidiary, DLPL Dubai, completed the acquisition of an 80% stake in Sunshine Healthcare Limited, Ghana. Sunshine Healthcare is now a step-down subsidiary.

Dr. Lal Pathlabs Board Meeting Date

Dr. Lal PathLabs will hold a board meeting on November 04, 2026, to consider and approve standalone and consolidated financial results for the quarter ending September 30, 2026.

Dr. Lal Pathlabs Employee Stock Options

Designated persons and the company's Employee Welfare Trust disclosed multiple equity transactions, including ESOP exercises and market sales, in a recent regulatory filing.

Value

₹1.42 Cr

Dr. Lal Pathlabs Acquisition Worth ₹168 Cr

Dr. Lal Path Labs Ltd. will acquire a 70% stake in SN Genelab Private Limited for Rs. 168 Crore to strengthen its genomics diagnostics portfolio.

Value

₹168.0 Cr

Dr. Lal Pathlabs Acquisition Worth ₹199.5 Cr

Dr. Lal PathLabs approved the acquisition of a 70% stake in SN Genelab Private Limited for a total consideration of up to ₹199.5 Crore.

Value

₹199.5 Cr

Dr. Lal Pathlabs Other Announcement

Dr. Lal PathLabs discloses share transactions by designated persons and an employee welfare trust under PIT regulations.

Dr. Lal Pathlabs Other Announcement

Designated persons at Dr. Lal PathLabs Ltd disclosed three equity trades totaling Rs. 0.50 Crore, as mandated under Insider Trading regulations.

Value

₹0.50 Cr